Resverlogix Competitors and Similar CompaniesClear all

Resverlogix's competitors and similar companies include AnGes, CRISPR Therapeutics, Lexicon Pharmaceuticals and Omega Therapeutics.

	Resverlogix Resverlogix is a clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.	AnGes AnGes is a biopharmaceutical company specializing in R&D and practical application of genetic medicine.	CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	Omega Therapeutics Omega Therapeutics is an epigenomic medicine company.
Founding Date	Founding Date 2001	Founding Date 1999	Founding Date 2013	Founding Date 1995	Founding Date 2017
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Calgary, CA HQ San Francisco, US	Locations Ibaraki, JP HQ Fujisawa, JP Ibaraki, JP Kawasaki, JP Minato City, JP Bethesda, US	Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Cambridge, US HQ
Employees	Employees 19	Employees 5562% decrease	Employees 393	Employees 20216% increase	Employees 60
Valuation ($)	Valuation ($) 12.9 m	Valuation ($) 78.3 m	Valuation ($) 4.2 b	Valuation ($) 737.4 m	Valuation ($) 68.4 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥874.1m (FY, 2025)	Revenue (est.) $3.5m (FY, 2025)	Revenue (est.) $49.8m (FY, 2025)	Revenue (est.) $3.1m (FY, 2023)
Cost of goods	Cost of goods N/A	Cost of goods ¥499.9m (FY, 2025)	Cost of goods N/A	Cost of goods $274k (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $50k (FY, 2025)	Gross profit ¥374.2m (FY, 2025)	Gross profit N/A	Gross profit $49.5m (FY, 2025)	Gross profit N/A
Net income	Net income ($7.8m) (FY, 2025)	Net income (¥5.1b) (FY, 2025)	Net income ($581.6m) (FY, 2025)	Net income ($50.3m) (FY, 2025)	Net income ($97.4m) (FY, 2023)
Funding
Total funding raised	Total funding raised $ 10m	Total funding raised N/A	Total funding raised $ 127m	Total funding raised $ 244.7m	Total funding raised $ 211m